A Novel Cancer Stemness-Related Signature for Predicting Prognosis in Patients with Colon Adenocarcinoma

Abstract

Objective. To explore the cancer stemness features and develop a novel cancer stemness-related prognostic signature for colon adenocarcinoma (COAD). Methods. We downloaded the mRNA expression data and clinical data of COAD from TCGA database and GEO database. Stemness index, mRNAsi, was utilized to investigate cancer stemness features. Weighted gene coexpression network analysis (WGCNA) was used to identify cancer stemness-related genes. Univariate and multivariate Cox regression analyses were applied to construct a prognostic risk cancer stemness-related signature. We then performed internal and external validation. The relationship between cancer stemness and COAD immune microenvironment was investigated. Results. COAD patients with higher mRNAsi score or EREG-mRNAsi score have significant longer overall survival (OS). We identified 483 differently expressed genes (DEGs) between the high and low mRNAsi score groups. We developed a cancer stemness-related signature using fifteen genes (including RAB31, COL6A3, COL5A2, CCDC80, ADAM12, VGLL3, ECM2, POSTN, DPYSL3, PCDH7, CRISPLD2, COLEC12, NRP2, ISLR, and CCDC8) for prognosis prediction of COAD. Low-risk score was associated with significantly preferable OS in comparison with high-risk score, and the area under the ROC curve (AUC) for OS prediction was 0.705. The prognostic signature was an independent predictor for OS of COAD. Macrophages, mast cells, and T helper cells were the vital infiltration immune cells, and APC costimulation and type II IFN response were the vital immune pathways in COAD. Conclusions. We developed and validated a novel cancer stemness-related prognostic signature for COAD, which would contribute to understanding of molecular mechanism in COAD.

Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma

“…These results were then used to calculate the AUC values to assess whether the signature could successfully predict the overall survival of COAD patients in the training cohort. The AUCs of our laRlncRNA pairs-based signature for 1, 3, and 5 years were 0.749, 0.752and 0.772, respectively, whereas those obtained in three other lncRNA-based signature studies on COAD patients were much lower, which were ZhangLncSig ( 76 ), WangLncSig ( 77 ) and XingLncSig ( 78 ), respectively in Figure 4F ( Figure S3 showed the GEO cohort validation results) . In comparison to other traditional clinical pathological variables, the AUCs of our risk signature showed great accuracy in predicting prognosis of patients with COAD ( Figure 4G ) .…”

Characterization of aging cancer-associated fibroblasts draws implications in prognosis and immunotherapy response in low-grade gliomas

“…Meflin has been also reported to correlate with favorable prognosis and therapeutic response to immune checkpoint blockage treatment in patients with non-small cell lung cancer (NSCLC) ( Miyai et al, 2022 ). Alternatively, meflin is determined as an unfavorable gene with a predictive value in patients with colon adenocarcinoma ( Wang et al, 2021 ). Consistently, univariate Cox regression analysis revealed that meflin ( ISLR ) served as an unfavorable gene in LGGs in our research.…”

The Value of the Stemness Index in Ovarian Cancer Prognosis

“…Zhao et al verified that high levels of MFAP4 expression predict platinum-based chemotherapy resistance and imply a poor prognosis in patients with serous OC [ 45 ]. CCDC80 is a common tumor stemness marker used in a variety of solid tumor prognostic models [ 46 , 47 , 48 ]. Studies have shown that it helps tumor cells acquire drug resistance and immune infiltration [ 46 ].…”